ArticlePediatric cardiology2026
Pulmonary Artery Pulsatility Index: A Novel Marker for Risk Assessment and Prognosis in Pediatric Idiopathic Pulmonary Arterial Hypertension.
Article in Pediatric cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The pulmonary artery pulsatility index (PAPi), calculated as (systolic pulmonary artery pressure - diastolic pulmonary artery pressure)/mean right atrial pressure). This study aimed to assess the clinical utility of PAPi in risk stratification for pediatric idiopathic pulmonary arterial hypertension (IPAH) and its performance in predicting the need for invasive intervention due to severe right heart failure. We analyzed clinical, echocardiographic, and right heart catheterization findings of 24 IPAH patients between April 2019 and November 2024. Statistical analyses included ROC curve analysis for PAPi's diagnostic performance, Kaplan-Meier survival analysis, and Cox regression for identifying independent predictors of intervention. The study included 24 patients (mean age 8.2 ± 4.7 years, 66.7% female). Based on pediatric risk classification, 45.8% were lower-risk, and 54.2% were high-risk, with PAPi significantly lower in high-risk patients (p < 0.001). ROC analysis identified PAPi < 3.24 as a strong predictor of high-risk status (sensitivity = 92%, specificity = 82%). PAPi correlated positively with 6MWT (r = 0.802) and TAPSE (r = 0.812) and negatively with WHO-FC (r = - 0.692) and NT-proBNP (r = - 0.713) (p < 0.001). Over 22 ± 15.9 months, 37.5% (n = 9) required invasive interventions for syncope, WHO-FC III/IV symptoms, or right ventricular failure, including atrial septostomy (77.8%), partial ASD closure (11.1%), and reverse Potts shunt (11.1%). Post-intervention, all but one patient improved. Patients requiring intervention had lower PAPi (1.88 ± 0.71 vs. 3.95 ± 1.27, p < 0.001). Kaplan-Meier analysis confirmed PAPi > 3.24 was associated with longer event-free survival (p = 0.002). Cox regression showed higher PAPi independently predicted lower intervention risk (HR 0.36, p = 0.042). In conclusion, this study suggests that PAPi is a reliable prognostic marker for risk stratification and predicting the need for invasive intervention in pediatric IPAH.
Indexed as
Identifiers
40715799What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.